The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis

N. L. Hordvik, P. H. Sammut, C. G. Judy, S. J. Strizek, J. L. Colombo

Research output: Contribution to journalArticle

Abstract

Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo. Aerosols were administered with the first three of four chest physiotherapy sessions given 4 h apart. Spirometry was measured before and 45 min after 7:00 A.M. and 3:00 P.M. therapy and before therapy at 7:00 P.M. and 7:00 A.M. the next morning. The mean percent change in FVC, FEV1, and FEF25-75% at 7:00 A.M. was 10.7, 14.8, and 19.6% with albuterol versus 2.4, 1.0, and -0.8% with placebo (p = 0.0012, < 0.0001, and = 0.003. respectively). A greater than 8% change in FEV1 separated changes with albuterol versus placebo with 96% specificity and occurred in 75% of all patients with albuterol; 71% at 7:00 A.M. versus 24% at 3:00 P.M. The reduction in response at 3:00 P.M. (p < 0.01) was presumably due to prolonged effects of morning therapy (>4 h). Individual changes in spirometry were significantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M. The mean percent change for the FVC, FEV, and FEF25-75% across the day (7:00 A.M. pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versus 3.9, 3.5, and 2.6% with placebo (p = 0.029, 0.036, and 0.232. respectively). The more positive and homogeneous changes in spirometry with albuterol, along with greater changes in these measures across the day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of hospitalized patients with cystic fibrosis. Comments. Seventy-five percent of all CF patients in North America and Europe receive bronchodilator therapy, presumably before chest physiotherapy, without any studies of efficacy. This excellent paper clearly shows that albuterol is efficacious in hospitalized CF patients.

Original languageEnglish (US)
Number of pages1
JournalPediatric Pulmonology
Volume23
Issue number4
StatePublished - Dec 1 1997

Fingerprint

Albuterol
Cystic Fibrosis
Placebos
Lung
Spirometry
Aerosols
Thorax
Bronchodilator Agents
North America
Cross-Over Studies
Inhalation
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. / Hordvik, N. L.; Sammut, P. H.; Judy, C. G.; Strizek, S. J.; Colombo, J. L.

In: Pediatric Pulmonology, Vol. 23, No. 4, 01.12.1997.

Research output: Contribution to journalArticle

@article{1e213d931d7c4d9db5e77da4bdaa6d0a,
title = "The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis",
abstract = "Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo. Aerosols were administered with the first three of four chest physiotherapy sessions given 4 h apart. Spirometry was measured before and 45 min after 7:00 A.M. and 3:00 P.M. therapy and before therapy at 7:00 P.M. and 7:00 A.M. the next morning. The mean percent change in FVC, FEV1, and FEF25-75{\%} at 7:00 A.M. was 10.7, 14.8, and 19.6{\%} with albuterol versus 2.4, 1.0, and -0.8{\%} with placebo (p = 0.0012, < 0.0001, and = 0.003. respectively). A greater than 8{\%} change in FEV1 separated changes with albuterol versus placebo with 96{\%} specificity and occurred in 75{\%} of all patients with albuterol; 71{\%} at 7:00 A.M. versus 24{\%} at 3:00 P.M. The reduction in response at 3:00 P.M. (p < 0.01) was presumably due to prolonged effects of morning therapy (>4 h). Individual changes in spirometry were significantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M. The mean percent change for the FVC, FEV, and FEF25-75{\%} across the day (7:00 A.M. pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7{\%} with albuterol versus 3.9, 3.5, and 2.6{\%} with placebo (p = 0.029, 0.036, and 0.232. respectively). The more positive and homogeneous changes in spirometry with albuterol, along with greater changes in these measures across the day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of hospitalized patients with cystic fibrosis. Comments. Seventy-five percent of all CF patients in North America and Europe receive bronchodilator therapy, presumably before chest physiotherapy, without any studies of efficacy. This excellent paper clearly shows that albuterol is efficacious in hospitalized CF patients.",
author = "Hordvik, {N. L.} and Sammut, {P. H.} and Judy, {C. G.} and Strizek, {S. J.} and Colombo, {J. L.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "23",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis

AU - Hordvik, N. L.

AU - Sammut, P. H.

AU - Judy, C. G.

AU - Strizek, S. J.

AU - Colombo, J. L.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo. Aerosols were administered with the first three of four chest physiotherapy sessions given 4 h apart. Spirometry was measured before and 45 min after 7:00 A.M. and 3:00 P.M. therapy and before therapy at 7:00 P.M. and 7:00 A.M. the next morning. The mean percent change in FVC, FEV1, and FEF25-75% at 7:00 A.M. was 10.7, 14.8, and 19.6% with albuterol versus 2.4, 1.0, and -0.8% with placebo (p = 0.0012, < 0.0001, and = 0.003. respectively). A greater than 8% change in FEV1 separated changes with albuterol versus placebo with 96% specificity and occurred in 75% of all patients with albuterol; 71% at 7:00 A.M. versus 24% at 3:00 P.M. The reduction in response at 3:00 P.M. (p < 0.01) was presumably due to prolonged effects of morning therapy (>4 h). Individual changes in spirometry were significantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M. The mean percent change for the FVC, FEV, and FEF25-75% across the day (7:00 A.M. pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versus 3.9, 3.5, and 2.6% with placebo (p = 0.029, 0.036, and 0.232. respectively). The more positive and homogeneous changes in spirometry with albuterol, along with greater changes in these measures across the day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of hospitalized patients with cystic fibrosis. Comments. Seventy-five percent of all CF patients in North America and Europe receive bronchodilator therapy, presumably before chest physiotherapy, without any studies of efficacy. This excellent paper clearly shows that albuterol is efficacious in hospitalized CF patients.

AB - Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo. Aerosols were administered with the first three of four chest physiotherapy sessions given 4 h apart. Spirometry was measured before and 45 min after 7:00 A.M. and 3:00 P.M. therapy and before therapy at 7:00 P.M. and 7:00 A.M. the next morning. The mean percent change in FVC, FEV1, and FEF25-75% at 7:00 A.M. was 10.7, 14.8, and 19.6% with albuterol versus 2.4, 1.0, and -0.8% with placebo (p = 0.0012, < 0.0001, and = 0.003. respectively). A greater than 8% change in FEV1 separated changes with albuterol versus placebo with 96% specificity and occurred in 75% of all patients with albuterol; 71% at 7:00 A.M. versus 24% at 3:00 P.M. The reduction in response at 3:00 P.M. (p < 0.01) was presumably due to prolonged effects of morning therapy (>4 h). Individual changes in spirometry were significantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M. The mean percent change for the FVC, FEV, and FEF25-75% across the day (7:00 A.M. pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versus 3.9, 3.5, and 2.6% with placebo (p = 0.029, 0.036, and 0.232. respectively). The more positive and homogeneous changes in spirometry with albuterol, along with greater changes in these measures across the day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of hospitalized patients with cystic fibrosis. Comments. Seventy-five percent of all CF patients in North America and Europe receive bronchodilator therapy, presumably before chest physiotherapy, without any studies of efficacy. This excellent paper clearly shows that albuterol is efficacious in hospitalized CF patients.

UR - http://www.scopus.com/inward/record.url?scp=33748166094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748166094&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748166094

VL - 23

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 4

ER -